283 related articles for article (PubMed ID: 31448717)
1. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
2. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
[TBL] [Abstract][Full Text] [Related]
3. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
4. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
5. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
6. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
Abdel Alem S; Elsharkawy A; El Akel W; Abdelaziz AO; Salama RM; El-Sayed MH; El Kassas M; Anees M; Shedeed M; Abdelsalam F; Ziada DH; El Shazly Y; El-Serafy M; Waked I; Esmat G; Doss W
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):1009-1016. PubMed ID: 31418303
[No Abstract] [Full Text] [Related]
7. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
8. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
9. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
10. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
11. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients.
Abdelsameea E; Alsebaey A; Abdel-Samiee M; Abdel-Razek W; Salama M; Waked I
Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1053-1059. PubMed ID: 33307880
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
13. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
14. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan.
Wang JH; Changchien CS; Hung CH; Tung WC; Kee KM; Chen CH; Hu TH; Lee CM; Lu SN
J Gastroenterol Hepatol; 2010 May; 25(5):964-9. PubMed ID: 20546451
[TBL] [Abstract][Full Text] [Related]
15. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
[TBL] [Abstract][Full Text] [Related]
17. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
18. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
19. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.
El-Garem H; AbdAllah M; Omar H; Cordie A; Abdel Alem S; Mohey Eldin Elzahry MA; Ghaith D; Abou El-Soud NH; Kamal W; Elsharkawy A; Esmat G
Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):693-698. PubMed ID: 31043104
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
